{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040894","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.825428+00:00","generated_at":"2026-06-11T18:05:23.755586+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IDEAYA Q2 net loss $27.9M, cash $510.1M; starts Phase 2/3 registrational trial for darovasertib","bullets":["Net loss of $27.9M for Q2 2023; accumulated deficit $287.0M; cash and securities $510.1M, funding into 2027.","Initiated Phase 2/3 registrational trial for darovasertib/crizotinib in first-line HLA-A2(-) metastatic uveal melanoma.","First patient dosed in Amgen-sponsored Phase 1/2 trial of IDE397 (MAT2A) + AMG 193 in MTAP-deletion solid tumors.","Anticipating FDA IND clearance in Q3 2023 for GSK101 Pol Theta Helicase inhibitor; $7M milestone due from GSK.","Targeting Werner Helicase development candidate with GSK in H2 2023, with potential $3M milestone from GSK."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040894","json":"https://secwatch.observer/filing/0000950170-23-040894.json","markdown":"https://secwatch.observer/filing/0000950170-23-040894.md","text":"https://secwatch.observer/filing/0000950170-23-040894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000095017023040894/0000950170-23-040894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000095017023040894/idya-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:05:23.755586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f188345e825a565a55ac3db1a67f7cc3f4e4dafb","claim":"IDEAYA Biosciences, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1676725/000095017023040894/0000950170-23-040894-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}